#Taiwan #Taipei #Formosa Pharmaceuticals #APP13007 #Samil Pharmaceuticals

Formosa Pharmaceuticals Partners with Samil for Eye Surgery Treatment

Formosa Pharmaceuticals, based in Taiwan, has announced a significant milestone in their partnership with Samil Pharmaceuticals, a notable South Korean company. The two firms have entered an exclusive licensing agreement that focuses on a new treatment solution aimed at aiding patient recovery from ocular surgeries. This collaboration centers on the commercialization of clobetasol propionate ophthalmic suspension (APP13007), a patented medication designed to relieve inflammation and pain after eye surgery.

Overview of the Agreement

The licensing deal will allow Samil Pharmaceuticals to exclusively market APP13007 in Vietnam, a country witnessing a rapid increase in cataract surgeries, with numbers approaching 300,000 annually. This agreement goes beyond mere rights; it includes an upfront payment, milestone payments based on regulatory progress, and royalties over the contract's term. Such structured financial arrangements not only benefit both pharmaceutical companies but also enhance the overall healthcare landscape in the region.

APP13007 is a 0.05% ophthalmic suspension utilizing clobetasol propionate, a highly effective corticosteroid. Formosa Pharmaceuticals developed this innovative formulation using their proprietary APNT® nanoparticle technology, which improves medicine delivery and bioavailability. Earlier FDA and Health Canada approvals underscore APP13007's potential in providing quick and sustained pain relief, a critical factor for patients undergoing eye surgery.

Market Potential

The ophthalmic corticosteroid market in Vietnam has shown promising growth. According to 2024 IQVIA sales data, it generated an annual sales value of $4.26 million. Samil’s expertise in ophthalmology, complemented by its long-standing relationships with global organizations like Samsung and Abbvie, positions the company for successful market penetration. The steady growth rate of 5% annually highlights a demand for effective aftercare solutions such as APP13007, which was supported by a US survey indicating that about 80% of patients experienced significant pain relief just four days post-surgery.

Erick Co, President and CEO of Formosa Pharmaceuticals expressed optimism about the partnership, stating, "We are pleased to collaborate with Samil again. Our joint efforts will assure better recovery for patients and strengthen our commitment to improving ophthalmic care in key regions."

On the other hand, Seung-Bum Huh, CEO of Samil Pharmaceuticals, stressed the growing competitiveness in the global ophthalmology market and reinforced the importance of this licensing agreement in strengthening their collaborative ties with Formosa Pharmaceuticals. They are both committed to advancing regulatory approvals and launching APP13007 in Vietnam, as well as continuing the preparations for the South Korean market.

Future Implications

This partnership marks a crucial step in both companies' strategies to address the increasing needs of ophthalmic patients in Vietnam and beyond. With growth in the cataract surgery field and the introduction of innovative treatments, there's potential for enhanced post-surgical care in a vital segment of healthcare services. The partnership not only reflects Formosa's and Samil’s commitment to product development but also highlights the dedication needed to tackle the challenges of delivering effective medical treatments to patients.

In summary, the exclusive licensing deal between Formosa Pharmaceuticals and Samil Pharmaceuticals's offers a promising future for ophthalmic treatments in Vietnam. As both companies prepare for regulatory pathways and launch derails, the hope is to significantly improve recovery experiences for patients undergoing ocular surgeries, thereby positively impacting overall healthcare outcomes.